Related Experiment Video

Updated: Jun 16, 2026

Preparation of Tumor Antigen-loaded Mature Dendritic Cells for Immunotherapy
08:40

Preparation of Tumor Antigen-loaded Mature Dendritic Cells for Immunotherapy

Published on: August 1, 2013

Presentation of tumour antigens by dendritic cells and challenges faced

Neil C Robson1, Sabine Hoves, Eugene Maraskovsky

  • 1School of Biological Sciences, The University of Edinburgh, Edinburgh, Scotland, United Kingdom.

Current Opinion in Immunology
|February 2, 2010
PubMed

Insights

Dendritic cell (DC) cancer vaccines show promise but often fail clinically. Re-evaluating DC vaccine strategies with new insights into DC biology and tumor immunology is crucial for success.

Area of Science:

  • Immunology
  • Oncology
  • Vaccinology

Background:

  • Dendritic cells (DCs) are key for anti-tumor immunity by presenting tumor antigens (T-Ags) to T cells.
  • DCs' cross-presentation of exogenous Ags on MHC class I molecules is vital for generating T-Ag-specific cytotoxic T lymphocytes (CTLs).
  • DC-based cancer immunotherapies have largely failed to meet clinical endpoints despite inducing T cell responses.

Purpose of the Study:

  • To re-evaluate dendritic cell (DC)-based vaccine strategies in cancer immunotherapy.
  • To incorporate recent advancements in DC biology and tumor immunology into vaccine design.
  • To address challenges hindering the clinical success of DC-based cancer vaccines.

Main Methods:

  • Review of scientific and clinical studies on dendritic cell (DC) applications in cancer immunotherapy.
  • Analysis of DC antigen-processing pathways and the role of adjuvants.
  • Examination of strategies to overcome tumor-mediated immune evasion.

Main Results:

  • DC-based strategies can induce T cell responses in cancer patients.
  • Clinical studies indicate a significant failure of DC-based approaches to meet endpoints.
  • There is a critical need to refine DC vaccine strategies based on current knowledge.

Conclusions:

  • Current DC-based cancer vaccine strategies require re-evaluation and improvement.
  • Optimizing DC function, including antigen processing and presentation, is essential.
  • Addressing tumor immune escape mechanisms is critical for effective DC-based immunotherapy.

More Related Videos

Tractable In Vivo Reprogramming of Tumor Cells to Type 1 Conventional Dendritic Cell-like Cells10:04

Tractable In Vivo Reprogramming of Tumor Cells to Type 1 Conventional Dendritic Cell-like Cells

Published on: August 1, 2025

Isolation Protocol of Mouse Monocyte-derived Dendritic Cells and Their Subsequent In Vitro Activation with Tumor Immune Complexes11:48

Isolation Protocol of Mouse Monocyte-derived Dendritic Cells and Their Subsequent In Vitro Activation with Tumor Immune Complexes

Published on: May 31, 2018

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Antigen Presenting Cells01:22

Antigen Presenting Cells

The immune system is a complex network of cells and molecules that protects the body from foreign invaders. T cells, a type of white blood cell, play a crucial role in this process. They recognize and attack foreign substances, such as pathogens, that enter the body.
T cells require the help of antigen-presenting cells (APCs), which process foreign antigens into smaller fragments that can be recognized by T cells. These APCs are highly specialized cells that efficiently internalize antigens...
Antigens Involved in Adaptive Immunity01:26

Antigens Involved in Adaptive Immunity

An antigen is any substance the immune system identifies as foreign and potentially harmful to the body, prompting an immune response. Antigens have two functional properties: immunogenicity and reactivity. Immunogenicity is the ability of an antigen to stimulate a specific immune response. At the same time, reactivity describes the antigen's ability to react with the cells and antibodies produced in response to it.
Complete Antigens
Complete antigens possess both immunogenicity and reactivity.
T Cell Activation and Clonal Selection01:22

T Cell Activation and Clonal Selection

T cells are integral to our adaptive immune system, recognizing and effectively responding to foreign antigens. T cell activation and clonal selection are pivotal in orchestrating this immune response. This article elucidates these mechanisms, detailing the roles of cluster of differentiation (CD) markers, major histocompatibility complex (MHC) molecules, costimulatory signals, and the process of clonal selection.
Naive T cells that have not yet encountered an antigen express two primary CD...
Antigen Processing Pathways01:31

Antigen Processing Pathways

MHC molecules are key players in the immune response, enabling T cells to recognize and respond to specific antigens. They are present on the surface of all nucleated cells in the body and are instrumental in presenting antigens to T cells and activating them. T cells recognize the MHC-antigen complex and initiate an immune response. MHC class I and MHC class II are two main types of MHC molecules, each associated with a distinct antigen processing pathway.
MHC Class I: Presenting Endogenous...
Cell-mediated Immune Responses01:40

Cell-mediated Immune Responses

Overview